- Home
- YJ vs PPBT Comparison
YJ vs PPBT Comparison
Compare YJ & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YJ
- PPBT
- Stock Information
- Founded
- YJ 2015
- PPBT 2010
- Country
- YJ China
- PPBT Israel
- Employees
- YJ N/A
- PPBT N/A
- Industry
- YJ Other Specialty Stores
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- YJ Consumer Discretionary
- PPBT Health Care
- Exchange
- YJ Nasdaq
- PPBT Nasdaq
- Market Cap
- YJ 7.9M
- PPBT 6.3M
- IPO Year
- YJ 2019
- PPBT N/A
- Fundamental
- Price
- YJ $1.80
- PPBT $2.62
- Analyst Decision
- YJ
- PPBT Strong Buy
- Analyst Count
- YJ 0
- PPBT 1
- Target Price
- YJ N/A
- PPBT $33.00
- AVG Volume (30 Days)
- YJ 11.9K
- PPBT 30.8K
- Earning Date
- YJ 06-17-2025
- PPBT 05-21-2025
- Dividend Yield
- YJ N/A
- PPBT N/A
- EPS Growth
- YJ N/A
- PPBT N/A
- EPS
- YJ N/A
- PPBT N/A
- Revenue
- YJ $57,219,520.00
- PPBT N/A
- Revenue This Year
- YJ N/A
- PPBT N/A
- Revenue Next Year
- YJ N/A
- PPBT N/A
- P/E Ratio
- YJ N/A
- PPBT N/A
- Revenue Growth
- YJ N/A
- PPBT N/A
- 52 Week Low
- YJ $1.37
- PPBT $2.00
- 52 Week High
- YJ $3.16
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- YJ 59.87
- PPBT 56.64
- Support Level
- YJ $1.45
- PPBT $2.46
- Resistance Level
- YJ $2.12
- PPBT $2.80
- Average True Range (ATR)
- YJ 0.10
- PPBT 0.20
- MACD
- YJ 0.03
- PPBT 0.04
- Stochastic Oscillator
- YJ 52.24
- PPBT 66.96
About YJ Yunji Inc. American Depository Shares
Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.